Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. - Concepedia

Concepedia

Publication | Closed Access

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

177

Citations

0

References

1993

Year

Joseph A. Sparano, Richard I. Fisher, Margaret C. Sunderland, Kim Margolin, Mary Lou Ernest, Mario Sznol, Michael B. Atkins, Janice P. Dutcher, Kenneth C. Micetich, Geoffrey R. Weiss

Journal of Clinical Oncology

Abstract

Using the preparation, dose, and schedule of IL-2 in our trial, IFN-alpha failed to enhance significantly the response rate to high-dose IL-2 in the treatment of patients with advanced melanoma.